✦ LIBER ✦

Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases

✍ Scribed by Hofbauer, Lorenz C.

Book ID: 121203051
Publisher: American Medical Association
Year: 2004
Tongue: English
Weight: 162 KB
Volume: 292
Category: Article
ISSN: 0098-7484
DOI: 10.1001/jama.292.4.490

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RANKL, RANK, osteoprotegerin: key partne

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

✍ M. Baud’huin; F. Lamoureux; L. Duplomb; F. Rédini; D. Heymann 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 911 KB

Cytokines, Osteoprotegerin, and RANKL In

Cytokines, Osteoprotegerin, and RANKL In Vitro and Histomorphometric Indices of Bone Turnover in Patients With Different Bone Diseases

✍ Heide Siggelkow; Thorsten Eidner; Gabriele Lehmann; Volker Viereck; Dirk Raddatz 📂 Article 📅 2003 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 244 KB

The abundant synovial expression of the

The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation

✍ Bernard Vandooren; Tineke Cantaert; Troy Noordenbos; Paul P. Tak; Dominique Baet 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 856 KB

Clinical Potential of RANKL Inhibition f

Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases

✍ Delmas, Pierre D. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 685 KB

The effect of zoledronic acid on serum D

The effect of zoledronic acid on serum Dickkopf-1, osteoprotegerin and rankl in patients with paget's disease of bone

✍ S.A. Polyzos; A.D. Anastasilakis; Z. Efstathiadou; M. Kita; I. Litsas; A. Avrami 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Receptor activator of nuclear factor-κB

Receptor activator of nuclear factor-κB ligand and osteoprotegerin : Potential implications for the pathogenesis and treatment of malignant bone diseases

✍ Lorenz C. Hofbauer; Andreas Neubauer; Armin E. Heufelder 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Background: The current review summarizes the roles of the ligand, receptor activator of nuclear factor-kappab ligand (rankl), its receptor, receptor activator of nuclear factor-kappab (rank), and its decoy receptor, osteoprotegerin (opg), on osteoclast biology and bone resorption. furthermore,